Cited by 506Retinal Diseases and TreatmentsGenetic Associations and EpidemiologyRetinal Development and Disorders

Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration

Open access
Chen, Wei, Stambolian, Dwight, Edwards, Albert O., Branham, Kari E., Othman, Mohammad, Jakobsdottir, Johanna, Tosakulwong, Nirubol, Pericak-Vance, Margaret A. +161 more·2010·Proceedings of the National Academy of Sciences

Abstract

We executed a genome-wide association scan for age-related macular degeneration (AMD) in 2,157 cases and 1,150 controls. Our results validate AMD susceptibility loci near CFH ( P < 10 −75 ), ARMS2 ( P < 10 −59 ), C2/CFB ( P < 10 −20 ), C3 ( P < 10 −9 ), and CFI ( P < 10 −6 ). We compared our top findings with the Tufts/Massachusetts General Hospital genome-wide association study of advanced AMD (821 cases, 1,709 controls) and genotyped 30 promising markers in additional individuals (up to 7,749 cases and 4,625 controls). With these data, we identified a susceptibility locus near TIMP3 (overall P = 1.1 × 10 −11 ), a metalloproteinase involved in degradation of the extracellular matrix and previously implicated in early-onset maculopathy. In addition, our data revealed strong association signals with alleles at two loci ( LIPC , P = 1.3 × 10 −7 ; CETP , P = 7.4 × 10 −7 ) that were previously associated with high-density lipoprotein cholesterol (HDL-c) levels in blood. Consistent with the hypothesis that HDL metabolism is associated with AMD pathogenesis, we also observed association with AMD of HDL-c—associated alleles near LPL ( P = 3.0 × 10 −3 ) and ABCA1 ( P = 5.6 × 10 −4 ). Multilocus analysis including all susceptibility loci showed that 329 of 331 individuals (99%) with the highest-risk genotypes were cases, and 85% of these had advanced AMD. Our studies extend the catalog of AMD associated loci, help identify individuals at high risk of disease, and provide clues about underlying cellular pathways that should eventually lead to new therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0912702107

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Separate analysis of NV and GA cases showed ARMS2 risk alleles preferentially associated with risk of NV (ORNV=2.97, ORGA=2.50, pdifference=.0008).

    “Consistent with previous reports17,29,30, separate analysis of NV and GA cases showed ARMS2 risk alleles preferentially associated with risk of NV (ORNV=2.97, ORGA=2.50, pdifference=.0008)”
  • Association has been demonstrated with several additional loci, each providing an entry-point into AMD biology and potential therapeutic targets.

    “Association has also been demonstrated with several additional loci14–20, each providing an entry-point into AMD biology and potential therapeutic targets.”
  • CFH risk alleles preferentially associated with risk of GA (ORNV=2.34, ORGA=2.80, pdifference=.0006).

    “whereas CFH risk alleles preferentially associated with risk of GA (ORNV=2.34, ORGA=2.80, pdifference=.0006).”
  • The TMMG meta-analysis data set consisted of 1242 cases and 492 controls from the Tufts/MGH GWAS Cohort Study, 1355 cases and 1076 controls from the MMAP Cohort Study, 1188 controls from the MIGen Consortium Study, and 1378 controls from the GAIN Schizophrenia Study.

    “The TMMG meta-analysis data set consisted of: (i) 1242 cases and 492 controls from the Tufts/MGH GWAS Cohort Study (15), which were derived from ongoing AMD study protocols as described previously (8,15,24,35–37); (ii) 1355 cases and 1076 controls from the MMAP Cohort Study (16); (iii) 1188 controls from the (MIGen) Consortium Study (21) and (iv) 1378 controls from the GAIN Schizophrenia Study (22”
  • All samples included in this study met quality control measures.

    “All samples included in this study met quality control measures as described previously (15,16).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chen, W., Stambolian, D., Edwards, A. O., Branham, K. E., Othman, M., Jakobsdottir, J., Tosakulwong, N., Pericak-Vance, M. A., Campochiaro, P. A., Klein, M. L., Tan, P. L., Conley, Y. P., Kanda, A., Kopplin, L., Li, Y., Augustaitis, K. J., Karoukis, A. J., Scott, W. K., Agarwal, A., Kovach, J. L., Schwartz, S. G., Postel, E. A., Brooks, M., Baratz, K. H., Brown, W. L., Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) Research Group, Brucker, A. J., Orlin, A., Brown, G., Ho, A., Regillo, C., Donoso, L., Tian, L., Kaderli, B., Hadley, D., Hagstrom, S. A., Peachey, N. S., Klein, R., Klein, B. E. K., Gotoh, N., Yamashiro, K., Ferris, F., Fagerness, J. A., Reynolds, R., Farrer, L. A., Kim, I. K., Miller, J. W., Cortón, M., Carracedo, A., Sanchez-Salorio, M., Pugh, E. W., Doheny, K. F., Brion, M., DeAngelis, M. M., Weeks, D. E., Zack, D. J., Chew, E. Y., Heckenlively, J. R., Yoshimura, N., Iyengar, S. K., Francis, P. J., Katsanis, N., Seddon, J. M., Haines, J. L., Gorin, M. B., Abecasis, G. R., Swaroop, A., Johnson, R. N., Ai, E., McDonald, H. R., Stolarczuk, M., Pavan, P. R., Billiris, K. K., Iyer, M., Menosky, M. M., Pautler, S. E., Millard, S. M., Hubbard, B., Aaberg, T., DuBois, L., Lyon, A., Anderson-Nelson, S., Jampol, L. M., Weinberg, D. V., Muñana, A., Rozenbajgier, Z., Orth, D., Cohen, J., MacCumber, M., MacCumber, M., Figliulo, C., Porcz, L., Folk, J., Boldt, H. C., Russell, S. R., Ivins, R., Hinz, C. J., Barr, C. C., Bloom, S., Jaegers, K., Kritchman, B., Whittington, G., Heier, J., Frederick, A. R., Morley, M. G., Topping, T., Davis, H. L., Bressler, S. B., Bressler, N. M., Doll, W., Trese, M., Capone, A., Garretson, B. R., Hassan, T. S., Ruby, A. J., Osentoski, T., McCannel, C. A., Ruszczyk, M. J., Grand, G., Blinder, K., Holekamp, N. M., Joseph, D. P., Shah, G., Nobel, G. S., Antoszyk, A. N., Browning, D. J., Stallings, A. H., Singerman, L. J., Miller, D., Novak, M., Pendergast, S., Zegarra, H., Schura, S. A., Smith-Brewer, S., Davidorf, F. H., Chambers, R., Chorich, L., Salerno, J., Dreyer, R. F., Ma, C., Kopfer, M. R., Klein, M. L., Wilson, D. J., Nolte, S. K., Grunwald, J. E., Brucker, A. J., Dunaief, J., Fine, S. L., Maguire, A. M., Stoltz, R. A., McRay, M. N., Fish, G. E., Anand, R., Spencer, R., Arnwine, J., Chandra, S. R., Altaweel, M., Blodi, B., Gottlieb, J., Ip, M., Nork, T. M., Perry-Raymond, J., Fine, S. L., Maguire, M. G., Brightwell-Arnold, M., Harkins, S., Peskin, E., Ying, G.-S., & Kurinij, N.
Affiliations
  • University of Michigan (US)
  • University of Pennsylvania (US)
  • Mayo Clinic (US)
  • University of Pittsburgh, Pittsburgh, PA 15260;
  • University of Miami Miller School of Medicine, Miami, FL 31136;
  • Johns Hopkins University (US)
  • University of Pittsburgh (US)
  • National Institutes of Health (US)
  • Case Western Reserve University (US)
  • University of Miami (US)
  • Vanderbilt University Medical Center (US)
  • Duke Medical Center (US)
  • Thomas Jefferson University (US)
  • Philadelphia Retina Endowment Fund, Philadelphia, PA 19107;
  • Louis Stokes Cleveland VA Medical Center (US)
  • University of Wisconsin–Madison (US)
  • Kyoto University (JP)
  • Broad Institute (US)
  • Tufts University (US)
  • Boston University (US)
  • Massachusetts Eye and Ear Infirmary (US)
  • Universidade de Santiago de Compostela (ES)
  • University of Santiago de Compostela, 15705 Santiago de Compostela, Spain;
  • Instituto Gallego de Oftalmología, 15706 Santiago de Compostela, Spain;
  • Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain;
  • Oregon Health & Science University (US)
  • University of California, Los Angeles (US)
  • Vanderbilt University (US)
  • Harvard University (US)
  • Cleveland Clinic (US)
Venue
Proceedings of the National Academy of Sciences
Published
2010-04-12
Volume
107
Issue
16
Pages
7401-7406
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1993904263
Cited by
506
References
38
Citations by year
2026: 8 · 2025: 13 · 2024: 19 · 2023: 9 · 2022: 20 · 2021: 17 · 2020: 22 · 2019: 31 · 2018: 26 · 2017: 32 · 2016: 35 · 2015: 49 · 2014: 44 · 2013: 54 · 2012: 53
FWCI
63.16
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Mayo Clinic
  • Pew Charitable Trusts
  • American Health Assistance Foundation
  • Foundation Fighting Blindness
  • Research to Prevent Blindness (P30 EY014801)
  • Massachusetts General Hospital
  • Tufts Medical Center
  • Macula Vision Research Foundation
  • Johns Hopkins University (HHSN268200782096C)
  • Louis and Harold Price Foundation
  • National Institutes of Health (Z99 EY999999, HHSN268200782096C, EY014801)
  • Japan Society for the Promotion of Science (22890007)
  • National Heart, Lung, and Blood Institute (U01HL084729, HL-084729)
  • National Human Genome Research Institute (R01HG002651, HG002651, HHSN268200782096C)
  • National Eye Institute (EY 09859, EY014467, EY 014801, R01EY007758, R01EY009859, R01EY012118, R01EY009769, EY 007758, EY-014458, R01EY014467, U10EY012118, EY012118, R01EY016862, R01EY011309, R01EY014458, EY016862, ZIAEY000489, P30EY014801)
  • National Institute of General Medical Sciences (T32GM007250)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
Keywords
age-related macular degeneration, genetic susceptibility loci, TIMP-3, high-density lipoprotein, HDL metabolism, hepatic lipase, cholesteryl ester transfer protein, lipoprotein lipase, ABCA1, complement factor H, ARMS2, complement C3, CFI, advanced AMD, multilocus analysis, extracellular matrix degradation
MeSH terms
Alleles, Chromosome Mapping, Genotype, Humans, Lipoproteins, HDL, Macular Degeneration, Regression Analysis, Risk, Genetic Variation, Case-Control Studies, Complement Factor I, Tissue Inhibitor of Metalloproteinase-3, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Genome-Wide Association Study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review